PCVX241220P150000
- 37.00
- 0.000.00%
Vaxcyte Newsroom
BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $135
BTIG Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $160
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $140
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Announces Target Price $135
Vaxcyte's Promising Clinical Advances and Strategic Plans Drive Buy Rating With $135 Price Target
Mizuho Securities Maintains Vaxcyte(PCVX.US) With Buy Rating
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating
TD Cowen Reaffirms Their Buy Rating on Vaxcyte (PCVX)
Vaxcyte Is Maintained at Outperform by Mizuho
Vaxcyte Analyst Ratings
Mizuho Securities Maintains Vaxcyte(PCVX.US) With Buy Rating
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating
Guggenheim Maintains Vaxcyte(PCVX.US) With Buy Rating, Raises Target Price to $130
A Quick Look at Today's Ratings for Vaxcyte(PCVX.US), With a Forecast Between $113 to $160
Vaxcyte Is Maintained at Buy by B of A Securities
Vaxcyte's VAX-31 Vaccine Poised to Dominate PCV Market: A Comprehensive Buy Rating Analysis
Vaxcyte Analyst Ratings
Vaxcyte's V AX-31 Demonstrates Market Disruption Potential With Strong Clinical Trial Results; Buy Rating Reaffirmed With Increased Price Target